[go: up one dir, main page]

WO2006037993A3 - Marqueurs cancereux - Google Patents

Marqueurs cancereux Download PDF

Info

Publication number
WO2006037993A3
WO2006037993A3 PCT/GB2005/003813 GB2005003813W WO2006037993A3 WO 2006037993 A3 WO2006037993 A3 WO 2006037993A3 GB 2005003813 W GB2005003813 W GB 2005003813W WO 2006037993 A3 WO2006037993 A3 WO 2006037993A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
markers
ovarian
colorectal
tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003813
Other languages
English (en)
Other versions
WO2006037993A2 (fr
Inventor
Graeme Ian Murray
Colin Matheson Telfer
William Thomas Melvin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auvation Ltd
Original Assignee
Auvation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421914A external-priority patent/GB0421914D0/en
Priority claimed from GB0421913A external-priority patent/GB0421913D0/en
Priority claimed from GB0421918A external-priority patent/GB0421918D0/en
Priority claimed from GB0421917A external-priority patent/GB0421917D0/en
Priority claimed from GB0421920A external-priority patent/GB0421920D0/en
Priority claimed from GB0421919A external-priority patent/GB0421919D0/en
Application filed by Auvation Ltd filed Critical Auvation Ltd
Publication of WO2006037993A2 publication Critical patent/WO2006037993A2/fr
Publication of WO2006037993A3 publication Critical patent/WO2006037993A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des marqueurs jusque-là non caractérisés de cancers, par exemple des cancers de l'ovaire et colorectal, ainsi que leurs utilisations en tant que marqueurs diagnostiques et pronostiques de cancers, en particulier des cancers de l'ovaire et colorectal. Ces marqueurs sont les enzymes cytochromes p450: CYP51, CYP2S1, CYP2U1, CYP3A43, CYP4F11, CYP4X1, CYP4Z1, CYP26A1, CYP3A7, CYP2F1, CYP4V2 et CYP39. L'invention concerne également des méthodes et des matériaux associés d'utilisation desdits marqueurs dans le cadre d'une intervention thérapeutique pour les cancers de l'ovaire, colorectal et autres, par exemple pour cibler spécifiquement des cellules néoplasiques sans causer de toxicité significative dans les tissus sains, et pour fournir des méthodes permettant d'évaluer la capacité de composés thérapeutiques candidats à moduler l'activité biologique de cellules cancéreuses provenant de l'ovaire, du colon, du rectum ou d'autres tissus.
PCT/GB2005/003813 2004-10-02 2005-10-03 Marqueurs cancereux Ceased WO2006037993A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB0421914A GB0421914D0 (en) 2004-10-02 2004-10-02 Drug metabolising enzyme in cancer
GB0421913A GB0421913D0 (en) 2004-10-02 2004-10-02 Tumour-specific pro drug target
GB0421918A GB0421918D0 (en) 2004-10-02 2004-10-02 Cancer therapeutic target
GB0421917A GB0421917D0 (en) 2004-10-02 2004-10-02 Cancer diagnosis and therapy
GB0421917.6 2004-10-02
GB0421914.3 2004-10-02
GB0421920A GB0421920D0 (en) 2004-10-02 2004-10-02 Cytochrome P450 enzymes and cancer
GB0421918.4 2004-10-02
GB0421919.2 2004-10-02
GB0421913.5 2004-10-02
GB0421920.0 2004-10-02
GB0421919A GB0421919D0 (en) 2004-10-02 2004-10-02 Cytochrome P450 prodrug target

Publications (2)

Publication Number Publication Date
WO2006037993A2 WO2006037993A2 (fr) 2006-04-13
WO2006037993A3 true WO2006037993A3 (fr) 2006-06-15

Family

ID=35530799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003813 Ceased WO2006037993A2 (fr) 2004-10-02 2005-10-03 Marqueurs cancereux

Country Status (1)

Country Link
WO (1) WO2006037993A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104745592A (zh) * 2013-12-31 2015-07-01 第三军医大学第一附属医院 Cyp4v2基因突变体及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009114A1 (fr) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Procédés, kits et composés pour déterminer la réactivité au traitement d'un trouble pathologique par épothilones
ES2332557B1 (es) 2007-12-04 2011-02-02 Universidad Autonoma De Madrid Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal.
WO2012143380A1 (fr) * 2011-04-20 2012-10-26 F. Hoffmann-La Roche Ag Hyperfréquences pour analyse immunohistochimique
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PL3388075T3 (pl) 2015-03-27 2023-12-11 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów
WO2024223797A1 (fr) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Utilisation d'inhibiteurs de cyp3a4 pour le traitement d'infections par le virus de l'hépatite d (vhd)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUMARAKULASINGHAM MEERA ET AL: "Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 MAY 2005, vol. 11, no. 10, 15 May 2005 (2005-05-15), pages 3758 - 3765, XP009060128, ISSN: 1078-0432 *
MCKAY J A ET AL: "EXPRESSION OF CYTOCHROME P450 CYP1B1 IN BREAST CANCER", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 374, 1995, pages 270 - 272, XP000615313, ISSN: 0014-5793 *
MURRAY G I ET AL: "CYTOCHROME P450 EXPRESSION IS A COMMON MOLECULAR EVENT IN SOFT TISSUE SARCOMAS", JOURNAL OF PATHOLOGY, CHICHESTER, SUSSEX, GB, vol. 171, no. 1, 1 September 1993 (1993-09-01), pages 49 - 52, XP000196718, ISSN: 0022-3417 *
TSUNEDOMI RYOUTCHI ET AL: "Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 27, no. 3, September 2005 (2005-09-01), pages 661 - 667, XP009060122, ISSN: 1019-6439 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104745592A (zh) * 2013-12-31 2015-07-01 第三军医大学第一附属医院 Cyp4v2基因突变体及其应用
CN104745592B (zh) * 2013-12-31 2020-02-21 第三军医大学第一附属医院 Cyp4v2基因突变体及其应用

Also Published As

Publication number Publication date
WO2006037993A2 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2004079368A3 (fr) Marqueurs cancereux
Pham-Ledard et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma
WO2006047483A3 (fr) Expansion dynamique des suppressions genomiques et formulation de jeux de marqueurs moleculaires pour diagnostic integre de pathologie moleculaire et caracterisation des echantillons de tissus, de fluides cellulaires et de fluides purs
WO2008028926A3 (fr) Procédés et compositions pour la prédiction d'une réponse à un régime de chimiothérapie contenant le trastuzumab dans une néoplasie maligne
Suzuki et al. RETRACTED: Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer
Sharma et al. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease
WO2004065583A3 (fr) Marqueurs d'expression genique pour le pronostic du cancer du sein
Kim et al. Genetic and clinical characteristics of phyllodes tumors of the breast
ES2356080T3 (es) Moesina, caveolina y proteina 1 asociada a yes como marcadores de respuesta a dasatinib en canceres de mama.
WO2008008315A3 (fr) COMPOSITIONS ET MÉTHODES VISANT À INHIBER LA CROISSANCE DE CANCERS À DÉFICIENCE EN smad4
WO2005062977A3 (fr) Anticorps humains d'internalisation specifiques du cancer de la prostate
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2006037993A3 (fr) Marqueurs cancereux
US20090076098A1 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
ATE331958T1 (de) Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen
WO2006133923A3 (fr) Diagnostic, pronostic, et prediction de la recurrence des cancers du sein
WO2007107774A3 (fr) Nouvelles méthodes de diagnostic et de traitement
WO2003083102A3 (fr) Proteines phosphatases associees au cancer et leurs utilisations
Susini et al. FGD3 gene as a new prognostic factor in breast cancer
ES2685709T3 (es) Biomarcador predictivo mediado por un inhibidor de CDK útil para la terapia contra el cáncer
Leppert et al. The role of molecular markers in the staging of renal cell carcinoma.
Huang et al. BLZF1 expression is of prognostic significance in hepatocellular carcinoma
Zakrzewska et al. Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma
Ji et al. Correlation study showing no concordance between EPAS-1/HIF-2α mRNA and protein expression in transitional cellcancer of the bladder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05789155

Country of ref document: EP

Kind code of ref document: A2